INSTITUTE FOR RATIONAL PHARMACOTHERAPY (IRF)

The aim of the IRF is to promote the most rational use of current and future medicinal products with respect to both pharmacological and economical aspects. This aim is directed towards both primary and hospital care. 

 

 Read more about IRF

REVIEWS

Euthyrox (levothyroxin)

08 February 2010


Multaq (dronedarone)

28 January 2010


Cimzia (certolizumab pegol)

06 January 2010


Simponi (golimumab)

06 January 2010


Onglyza (saxagliptin)

06 January 2010


Ellaone (30 mg ulipristal acetate)

06 January 2010


When new products that are of general medical interest enter the Danish market or there are special changes made in already marketed products, the Institute for Rational Pharmacotherapy prepares a short description of how the product should be used within a context of the other available therapies.

 

Go to Reviews

Selected webpages

From the Danish Medicines Agency and IRF:

Ordiprax

Interaction database

Danish Medicines Agency

Summaries of Product Characteristics

Reimbursement

Medicine prices


Page last updated: 21 January 2010 Institut for Rationel Farmakoterapi - Axel Heides Gade 1 - 2300 København S - tlf. +45 44 88 91 21 - E-mail: irf@dkma.dk